GlobeNewswire: AxoGen, Inc. Contains the last 10 of 273 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T04:41:03ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/05/2840267/0/en/Axogen-Inc-Reports-2023-Fourth-Quarter-and-Full-Year-Financial-Results.html?f=22&fvtc=4&fvtv=21601Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results2024-03-05T12:00:00Z<![CDATA[ALACHUA, Fla. and TAMPA, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2023.]]>https://www.globenewswire.com/news-release/2024/02/13/2828674/0/en/Axogen-Inc-to-Report-2023-Fourth-Quarter-and-Full-Year-Financial-Results-on-March-5-2024.html?f=22&fvtc=4&fvtv=21601Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 20242024-02-13T21:30:00Z<![CDATA[ALACHUA, Fla. and TAMPA, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report 2023 fourth quarter and full-year financial results on Tuesday, March 5, 2024, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release.]]>https://www.globenewswire.com/news-release/2024/02/02/2823057/0/en/Company-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-C-4.html?f=22&fvtc=4&fvtv=21601Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)2024-02-02T21:15:00Z<![CDATA[ALACHUA, Fla. and TAMPA, Fla., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced making Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) in connection with the employment and appointment of John Manning to the position of Area Vice President of Sales. Mr. Manning will report to Doris Quackenbush, Vice President of Sales.]]>https://www.globenewswire.com/news-release/2024/01/18/2811999/0/en/Axogen-Inc-Announces-Positive-Topline-Results-from-REPOSE-a-Prospective-Randomized-Clinical-Trial-of-Axoguard-Nerve-Cap.html?f=22&fvtc=4&fvtv=21601Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap2024-01-18T22:00:00Z<![CDATA[REPOSE® met its primary endpoint of non-inferiority between the pain visual analog scale outcomes for neurectomy with Axoguard Nerve Cap® vs. standard-of-care neurectomy at Month 12.]]>https://www.globenewswire.com/news-release/2024/01/04/2804369/0/en/Axogen-Reports-Preliminary-Unaudited-Revenue-for-Fourth-Quarter-and-Full-Year-2023.html?f=22&fvtc=4&fvtv=21601Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 20232024-01-04T21:45:00Z<![CDATA[ALACHUA, Fla. and TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced preliminary unaudited fourth quarter and full-year 2023 revenue.]]>https://www.globenewswire.com/news-release/2024/01/04/2804365/0/en/Axogen-Announces-Plan-for-Leadership-Transition-with-CEO-Karen-Zaderej-to-Retire-from-Company-by-January-2025.html?f=22&fvtc=4&fvtv=21601Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 20252024-01-04T21:40:00Z<![CDATA[ALACHUA and TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that President and Chief Executive Officer (CEO) Karen Zaderej plans to retire from the Company by January 2025. The Company’s Board of Directors will retain an executive recruitment firm to manage a search for her successor. When a new CEO is in place, Ms. Zaderej will step down from her executive post and Board duties and continue as a consultant to Axogen for an additional nine months to support the leadership transition and the submission process of the Biologics License Application (BLA) for Avance® Nerve Graft. While the transition is planned to be no later than Jan. 5, 2025, it could occur sooner depending on the timing of a new CEO appointment.]]>https://www.globenewswire.com/news-release/2024/01/04/2804361/0/en/Axogen-Announces-Promotions-on-Research-and-Development-Team.html?f=22&fvtc=4&fvtv=21601Axogen Announces Promotions on Research and Development Team2024-01-04T21:35:00Z<![CDATA[Company Also Announces Departure of Angelo Scopelianos, Ph.D. Company Also Announces Departure of Angelo Scopelianos, Ph.D.]]>https://www.globenewswire.com/news-release/2023/12/26/2801164/0/en/Axogen-Inc-Appoints-Kathy-Weiler-to-its-Board-of-Directors.html?f=22&fvtc=4&fvtv=21601Axogen, Inc. Appoints Kathy Weiler to its Board of Directors2023-12-26T21:15:00Z<![CDATA[Weiler brings 20+ years of strategic and commercial leadership experience to the Axogen, Inc. Board of Directors Weiler brings 20+ years of strategic and commercial leadership experience to the Axogen, Inc. Board of Directors]]>https://www.globenewswire.com/news-release/2023/12/06/2791636/0/en/Axogen-Announces-Transition-of-Finance-Team-Leadership.html?f=22&fvtc=4&fvtv=21601Axogen Announces Transition of Finance Team Leadership2023-12-06T12:00:00Z<![CDATA[Nir Naor Appointed CFO to Replace Peter Mariani as Company Aligns Executive Team with Financial Management Needs for Next Phase of Growth Nir Naor Appointed CFO to Replace Peter Mariani as Company Aligns Executive Team with Financial Management Needs for Next Phase of Growth]]>https://www.globenewswire.com/news-release/2023/12/01/2789571/0/en/Company-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=21601Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2023-12-01T22:00:00Z<![CDATA[ALACHUA and TAMPA, Fla., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced making Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) in connection with the employment and appointment of Harold D. Tamayo as Vice President of Finance and Investor Relations. Mr. Tamayo will report to Peter J. Mariani, Executive Vice President and Chief Financial Officer, and will be responsible for Financial Planning and Analysis and Investor Relations.]]>